Streamlining “Library-to-Lead” for your Antibody Therapeutics

June 6, 2018

The number of therapeutic antibodies entering the market continues to grow annually, with 2017 seeing ten approvals in either the European Union or the United States supported by a robust late-stage clinical pipeline that will likely yield even more approved drugs in 2018 and 2019. Making a drug is an expensive and time-consuming endeavor requiring an incredible level of detail and rigor to ensure that drugs are safe, efficacious, manufacturable and convenient to administer to the patient. While antibody generation is highly commoditized, with modern in vivo and in vitro libraries typically producing vast numbers of clones, the analytical tools used to characterize them at the molecular level to understand their mechanism of action often fall orders of magnitude behind in throughput.

Spotlight

Pinnacle Biologics, Inc.

Pinnacle Biologics specializes in revitalizing healthcare therapies by promoting, developing and managing innovative approaches to the global commercialization of products in the oncology and specialty areas.

OTHER WHITEPAPERS
news image

Deck 7 Webinars and Virtual Events

whitePaper | January 1, 2020

If you recognize some of these challenges, download the Deck 7 Webinar & Virtual Events overview to see how we make it easy for busy marketers to run highly successful webinars and virtual events....

Read More
news image

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Read More
news image

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Read More
news image

The Annual Clinical Trials Round-up 2021

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

Read More
news image

Protein fingerprints pave the way for microarray comparison

whitePaper | June 9, 2022

Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More

Spotlight

Pinnacle Biologics, Inc.

Pinnacle Biologics specializes in revitalizing healthcare therapies by promoting, developing and managing innovative approaches to the global commercialization of products in the oncology and specialty areas.

Events